<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01997411</url>
  </required_header>
  <id_info>
    <org_study_id>16418</org_study_id>
    <secondary_id>I8R-MC-IGBB</secondary_id>
    <secondary_id>INGluc002</secondary_id>
    <secondary_id>AMG103</secondary_id>
    <nct_id>NCT01997411</nct_id>
  </id_info>
  <brief_title>Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes</brief_title>
  <official_title>Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Locemia Solutions ULC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess how glucagon administered nasally, using a nasal
      dosing delivery device, works in children and adolescents compared with
      commercially-available glucagon given by injection. In addition, the safety and tolerability
      of glucagon given nasally was evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was conducted to permit determination of appropriate dose level(s) for pediatric
      use based on the safety observations and results of glucagon and glucose assays.

      Each participant 12 to less than 17 years of age underwent two visits in random order and
      received glucagon nasal powder once and commercially available glucagon (GlucaGen, Novo
      Nordisk) by intramuscular (IM) injection once. Participants 4 to less than 12 years were
      randomly assigned to have either 1 visit with commercially available glucagon (GlucaGen, Novo
      Nordisk) by IM injection OR to have 2 visits with a 2.0 milligram (mg) dose of glucagon nasal
      powder administered during one visit and a 3.0 mg dose of glucagon nasal powder administered
      during the other visit. For those randomized to complete two research dosing visits, the dose
      of glucagon nasal powder given during each visit was masked to the participant and study
      personnel.

      Glucagon was administered after glucose was lowered to &lt;80 mg/dL using insulin if necessary
      on the dosing day. Participants were treated with either glucagon given nasally (either 2.0
      mg or 3.0 mg for participants 4 to less than 12 years of age or 3.0 mg for those 12 to less
      than 17 years of age) or by intramuscular (IM) injection (1 mg for those 55 pounds [lbs] or
      more and 0.5 mg for those weighing less than 55 lbs) in the quadriceps muscle of the leg.

      Blood glucose levels and adverse events were carefully monitored for 90 minutes post-dosing.
      After a wash-out period of 7 days or more, participants 12 to less than 17 years of age
      returned to the clinic and the procedure was repeated with each participant crossed over to
      the other treatment. Participants 4 to less than 12 years assigned to have 2 dosing visits
      returned to clinic for repeated procedures and received alternate dose of nasal glucagon
      (NG). Participants 4 to less than 12 years assigned to a single dosing visit did not return
      for a second dosing visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>IM and NG arms are open labeled. NG cohorts, 2mg and 3mg, are quadruple blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Change From Baseline Concentration (Cmax) of Glucagon</measure>
    <time_frame>Pre-dose; 5, 10, 15, 20, 30, 40, 60 and 90 minutes following glucagon administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon</measure>
    <time_frame>Pre-dose; 5, 10, 15, 20, 30, 40, 60 and 90 minutes following glucagon administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC0-1.5) of Baseline Adjusted Glucagon</measure>
    <time_frame>Pre-dose; 5, 10, 15, 20, 30, 40, 60 and 90 minutes following glucagon administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of Baseline-Adjusted Glucose</measure>
    <time_frame>Pre-dose; 5, 10, 15, 20, 30, 40, 60 and 90 minutes following glucagon administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose</measure>
    <time_frame>Pre-dose; 5, 10, 15, 20, 30, 40, 60 and 90 minutes following glucagon administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Effect Concentration Time Curve (AUEC0-1.5) of Baseline-Adjusted Glucose From Time Zero up to 90 Minutes</measure>
    <time_frame>Pre-dose; 5, 10, 15, 20, 30, 40, 60 and 90 minutes following glucagon administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nasal and Non-nasal Effects/Symptoms</measure>
    <time_frame>Pre-dose;15, 30, 60 and 90 minutes following glucagon administration</time_frame>
    <description>Symptoms of runny nose, nasal congestion and/or itching, sneezing, watery and/or itchy eyes, redness of eyes, and itching of ears and/or throat were assessed prior to administering glucagon and at 15, 30, 60 and 90 minutes following administration of glucagon. This was done via the &quot;Nasal Non-nasal Score Questionnaire&quot;. Each of the 9 symptoms is assigned an integer value from 0 to 3; higher values indicate more severe symptoms (a score of 0 indicates no symptoms). The reported results indicate the cohort median out of a possible maximum value of 27 (summing all 9 questions for each participant and reporting the median/IQR across participants).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving at Least a 25 mg/dL Rise in Blood Glucose Above Nadir Level Within 30 Minutes</measure>
    <time_frame>Pre-dose; 5, 10, 15, 20, and 30 minutes following glucagon administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieving â‰¥25 mg/dL Rise in Plasma Glucose Above Nadir Level Within 30 Minutes</measure>
    <time_frame>Pre-dose; 5, 10, 15, 20, and 30 minutes following glucagon administration</time_frame>
    <description>Time (in minutes) when all participants experienced a rise in glucose &gt;=25mg/dL. This is an absolute number and is not a calculated statistic. There is no distribution per cohort.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants With &gt;= 25 mg/dL Rise in Plasma Glucose Within 30 Minutes</measure>
    <time_frame>Pre-dose; 5, 10,15, 20, and 30 minutes following glucagon administration</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Nasal Glucagon (NG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal glucagon (NG) doses of 2.0 mg and 3.0 mg for participants 4 to less than 12 years of age and 3.0 mg for those 12 to less than 17 years of age were administered in a nostril with a prefilled delivery device that delivered a single dose upon activation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular (IM) Glucagon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who weighed at least 25 kilograms (kg)/55 pounds (lbs) were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 lbs, IM glucagon dosed with 0.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nasal Glucagon</intervention_name>
    <arm_group_label>Nasal Glucagon (NG)</arm_group_label>
    <other_name>AMG504-1</other_name>
    <other_name>LY900018</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular Glucagon</intervention_name>
    <arm_group_label>Intramuscular (IM) Glucagon</arm_group_label>
    <other_name>GlucaGen HypoKit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible, the following inclusion criteria were met:

          -  History of type 1 diabetes and receiving daily insulin therapy from the time of
             diagnosis for at least 12 months

          -  At least 4 years of age and less than 17 years

          -  Females must have met one of the following criteria:

               -  Of childbearing potential but agreed to use an accepted contraceptive regimen as
                  described in the study procedure manual throughout the entire duration of the
                  study (from screening until study completion)

               -  Of non-childbearing potential, defined as a female who had a hysterectomy or
                  tubal ligation, was clinically considered infertile or had not yet reached
                  menarche

          -  In good general health with no conditions that could have influenced the outcome of
             the trial, and in the judgment of the Investigator was a good candidate for the study
             based on review of available medical history, physical examination and clinical
             laboratory evaluations

          -  Willingness to adhere to the study requirements

        Exclusion Criteria:

        An individual was not eligible if any of the following exclusion criteria were present:

          -  Females who were pregnant according to a positive urine pregnancy test, actively
             attempting to get pregnant, or were lactating

          -  History of hypersensitivity to glucagon or any related products or severe
             hypersensitivity reactions (such as angioedema) to any drugs

          -  Presence of cardiovascular, gastrointestinal, liver or kidney disease, or any other
             conditions which in the judgment of the investigator could have interfered with the
             absorption, distribution, metabolism or excretion of drugs or could potentiate or
             predispose to undesired effects

          -  History of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma

          -  History of an episode of severe hypoglycemia (as defined by an episode that required
             third party assistance for treatment) in the 1 month prior to enrolling in the study

          -  Use of daily systemic beta-blocker, indomethacin, warfarin or anticholinergic drugs

          -  History of epilepsy or seizure disorder

          -  Use of an Investigational Product in another clinical trial within the past 30 days

          -  Blood donation in 3 months prior to first glucagon dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Davis Center for Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPA Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2013</study_first_posted>
  <results_first_submitted>September 2, 2016</results_first_submitted>
  <results_first_submitted_qc>January 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2017</results_first_posted>
  <last_update_submitted>August 1, 2018</last_update_submitted>
  <last_update_submitted_qc>August 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>4 to&lt;8 Years Old Intramuscular (IM) Glucagon Visit</title>
          <description>Participants who weighed at least 25 kilograms (kg)/55 pounds (lbs) were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.
This was completed at one visit and was the only visit for this cohort.</description>
        </group>
        <group group_id="P2">
          <title>4 to &lt;8 Years Old NG 2.0 mg 1st Visit/3.0 mg 2nd Visit</title>
          <description>At the first visit, a nasal glucagon (NG) dose of 2.0 milligrams (mg) for participants 4 to less than 8 years of age was administered nasally.
At the second visit, NG dose of 3.0 mg was administered nasally.</description>
        </group>
        <group group_id="P3">
          <title>4 to &lt;8 Years Old NG 3.0 mg 1st Visit/2.0 mg 2nd Visit</title>
          <description>At the first visit, a NG dose of 3.0 mg for participants 4 to less than 8 years of age was administered nasally.
At the second visit, a NG dose of 2.0 mg was administered nasally.</description>
        </group>
        <group group_id="P4">
          <title>8 to &lt;12 Years Old Intramuscular Glucagon Visit</title>
          <description>Participants who weighed at least 25 kilograms kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg. This was completed at one visit and was the only visit for this cohort.</description>
        </group>
        <group group_id="P5">
          <title>8 to &lt;12 Years Old NG 2.0 mg 1st Visit/3.0 mg 2nd Visit</title>
          <description>At the first visit, a NG dose of 2.0 mg for participants 8 to less than 12 years of age was administered nasally.
At the second visit, a NG dose of 3.0 mg was administered nasally.</description>
        </group>
        <group group_id="P6">
          <title>8 to &lt;12 Years Old NG 3.0 mg 1st Visit/2.0 mg 2nd Visit</title>
          <description>At the first visit, a NG dose of 3.0 mg for participants 8 to less than 12 years of age was administered nasally.
At the second visit, a NG dose of 2.0 mg was administered nasally.</description>
        </group>
        <group group_id="P7">
          <title>12 to &lt;17 Years Old NG 1st Visit/IM Glucagon 2nd Visit</title>
          <description>At the first visit, a NG dose of 3.0 mg was administered nasally.
At the second visit, participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
        </group>
        <group group_id="P8">
          <title>12 to &lt;17 Years Old IM Glucagon 1st Visit/NG 2nd Visit</title>
          <description>At the first visit, participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.
At the second visit, a NG dose of 3.0 mg was administered nasally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>4 to &lt;8 Years Old IM Glucagon Cohort</title>
          <description>Participants who were 4 to &lt; 8 years old at the time of enrollment into the study randomized to receive only the intramuscular glucagon at one visit.</description>
        </group>
        <group group_id="B2">
          <title>4 to &lt;8 Years Old NG Cohort</title>
          <description>Participants who were 4 to &lt; 8 years old at the time of enrollment into the study randomized to receive 2.0 or 3.0 mg of nasal glucagon at two separate visits. Order of these visits was randomized.</description>
        </group>
        <group group_id="B3">
          <title>8 to &lt;12 Years Old IM Glucagon Cohort</title>
          <description>Participants who were 8 to &lt; 12 years old at the time of enrollment into the study randomized to receive only the intramuscular glucagon at one visit.</description>
        </group>
        <group group_id="B4">
          <title>8 to &lt;12 Years Old NG Cohort</title>
          <description>Participants who were 8 to &lt; 12 years old at the time of enrollment into the study randomized to receive 2.0 or 3.0 mg of nasal glucagon at two separate visits. Order of these visits was randomized.</description>
        </group>
        <group group_id="B5">
          <title>12 to &lt;17 Years Old NG/IM Cohort</title>
          <description>Participants who were 12 to &lt; 17 years old at the time of enrollment into the study randomized to receive either intramuscular glucagon or nasal glucagon at two separate visits. Order of these visits was randomized.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.8" lower_limit="5.7" upper_limit="7.5"/>
                    <measurement group_id="B2" value="6.8" lower_limit="5.7" upper_limit="7.5"/>
                    <measurement group_id="B3" value="11.1" lower_limit="10.5" upper_limit="11.8"/>
                    <measurement group_id="B4" value="11.1" lower_limit="10.5" upper_limit="11.8"/>
                    <measurement group_id="B5" value="14.5" lower_limit="13.2" upper_limit="15.8"/>
                    <measurement group_id="B6" value="10.6" lower_limit="7.4" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Local HbA1c</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.6" spread="0.5"/>
                    <measurement group_id="B2" value="8.3" spread="0.8"/>
                    <measurement group_id="B3" value="7.5" spread="1.1"/>
                    <measurement group_id="B4" value="8.1" spread="0.7"/>
                    <measurement group_id="B5" value="8.2" spread="1.5"/>
                    <measurement group_id="B6" value="8.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" lower_limit="2.1" upper_limit="3.8"/>
                    <measurement group_id="B2" value="2.7" lower_limit="1.8" upper_limit="3.6"/>
                    <measurement group_id="B3" value="5.3" lower_limit="3.9" upper_limit="6.3"/>
                    <measurement group_id="B4" value="4.3" lower_limit="3.4" upper_limit="6.7"/>
                    <measurement group_id="B5" value="5.9" lower_limit="3.5" upper_limit="8.0"/>
                    <measurement group_id="B6" value="3.9" lower_limit="2.6" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Change From Baseline Concentration (Cmax) of Glucagon</title>
        <time_frame>Pre-dose; 5, 10, 15, 20, 30, 40, 60 and 90 minutes following glucagon administration</time_frame>
        <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
        <group_list>
          <group group_id="O1">
            <title>4 to&lt;8 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O2">
            <title>4 to&lt;8 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O3">
            <title>4 to&lt;8 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O4">
            <title>8 to &lt;12 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>8 to&lt;12 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O6">
            <title>8 to&lt;12 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O7">
            <title>12 to &lt;17 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O8">
            <title>12 to&lt;17 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 12 to less than 17 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Change From Baseline Concentration (Cmax) of Glucagon</title>
          <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
          <units>picograms per millilitre (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6290.33" spread="2045.96"/>
                    <measurement group_id="O2" value="3463.55" spread="1760.28"/>
                    <measurement group_id="O3" value="3958.58" spread="2438.60"/>
                    <measurement group_id="O4" value="4743.00" spread="3094.61"/>
                    <measurement group_id="O5" value="2776.27" spread="979.28"/>
                    <measurement group_id="O6" value="5664.33" spread="2114.69"/>
                    <measurement group_id="O7" value="4277.25" spread="3774.77"/>
                    <measurement group_id="O8" value="3103.25" spread="2302.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon</title>
        <time_frame>Pre-dose; 5, 10, 15, 20, 30, 40, 60 and 90 minutes following glucagon administration</time_frame>
        <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
        <group_list>
          <group group_id="O1">
            <title>4 to&lt;8 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O2">
            <title>4 to&lt;8 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O3">
            <title>4 to&lt;8 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O4">
            <title>8 to &lt;12 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>8 to&lt;12 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O6">
            <title>8 to&lt;12 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O7">
            <title>12 to &lt;17 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O8">
            <title>12 to&lt;17 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 12 to less than 17 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon</title>
          <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
          <units>hours (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" lower_limit="0.08" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.25" lower_limit="0.17" upper_limit="0.33"/>
                    <measurement group_id="O3" value="0.29" lower_limit="0.17" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.29" lower_limit="0.08" upper_limit="0.50"/>
                    <measurement group_id="O5" value="0.25" lower_limit="0.17" upper_limit="0.33"/>
                    <measurement group_id="O6" value="0.25" lower_limit="0.17" upper_limit="0.50"/>
                    <measurement group_id="O7" value="0.29" lower_limit="0.08" upper_limit="0.50"/>
                    <measurement group_id="O8" value="0.33" lower_limit="0.25" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC0-1.5) of Baseline Adjusted Glucagon</title>
        <time_frame>Pre-dose; 5, 10, 15, 20, 30, 40, 60 and 90 minutes following glucagon administration</time_frame>
        <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
        <group_list>
          <group group_id="O1">
            <title>4 to&lt;8 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O2">
            <title>4 to&lt;8 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O3">
            <title>4 to&lt;8 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O4">
            <title>8 to &lt;12 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>8 to&lt;12 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O6">
            <title>8 to&lt;12 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O7">
            <title>12 to &lt;17 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O8">
            <title>12 to&lt;17 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 12 to less than 17 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC0-1.5) of Baseline Adjusted Glucagon</title>
          <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
          <units>hour*picogram per millilitre (hr*pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4078.68" spread="2078.89"/>
                    <measurement group_id="O2" value="1744.36" spread="978.81"/>
                    <measurement group_id="O3" value="2472.40" spread="1435.45"/>
                    <measurement group_id="O4" value="3635.77" spread="2069.11"/>
                    <measurement group_id="O5" value="1506.23" spread="541.57"/>
                    <measurement group_id="O6" value="2939.31" spread="1042.03"/>
                    <measurement group_id="O7" value="3110.22" spread="2848.75"/>
                    <measurement group_id="O8" value="1999.69" spread="1329.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of Baseline-Adjusted Glucose</title>
        <time_frame>Pre-dose; 5, 10, 15, 20, 30, 40, 60 and 90 minutes following glucagon administration</time_frame>
        <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
        <group_list>
          <group group_id="O1">
            <title>4 to&lt;8 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O2">
            <title>4 to&lt;8 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O3">
            <title>4 to&lt;8 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O4">
            <title>8 to &lt;12 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>8 to&lt;12 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O6">
            <title>8 to&lt;12 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O7">
            <title>12 to &lt;17 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O8">
            <title>12 to&lt;17 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 12 to less than 17 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Baseline-Adjusted Glucose</title>
          <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.17" spread="26.57"/>
                    <measurement group_id="O2" value="118.18" spread="46.46"/>
                    <measurement group_id="O3" value="137.50" spread="42.14"/>
                    <measurement group_id="O4" value="130.50" spread="21.81"/>
                    <measurement group_id="O5" value="125.09" spread="23.81"/>
                    <measurement group_id="O6" value="132.82" spread="30.59"/>
                    <measurement group_id="O7" value="123.17" spread="29.58"/>
                    <measurement group_id="O8" value="102.33" spread="25.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose</title>
        <time_frame>Pre-dose; 5, 10, 15, 20, 30, 40, 60 and 90 minutes following glucagon administration</time_frame>
        <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
        <group_list>
          <group group_id="O1">
            <title>4 to&lt;8 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O2">
            <title>4 to&lt;8 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O3">
            <title>4 to&lt;8 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O4">
            <title>8 to &lt;12 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>8 to&lt;12 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O6">
            <title>8 to&lt;12 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O7">
            <title>12 to &lt;17 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O8">
            <title>12 to&lt;17 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 12 to less than 17 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose</title>
          <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
          <units>hours (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.67" upper_limit="1.50"/>
                    <measurement group_id="O2" value="0.67" lower_limit="0.33" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.50" upper_limit="1.50"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O5" value="1.00" lower_limit="0.67" upper_limit="1.50"/>
                    <measurement group_id="O6" value="1.00" lower_limit="0.50" upper_limit="1.50"/>
                    <measurement group_id="O7" value="1.00" lower_limit="0.67" upper_limit="1.50"/>
                    <measurement group_id="O8" value="1.00" lower_limit="0.50" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Effect Concentration Time Curve (AUEC0-1.5) of Baseline-Adjusted Glucose From Time Zero up to 90 Minutes</title>
        <time_frame>Pre-dose; 5, 10, 15, 20, 30, 40, 60 and 90 minutes following glucagon administration</time_frame>
        <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
        <group_list>
          <group group_id="O1">
            <title>4 to&lt;8 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O2">
            <title>4 to&lt;8 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O3">
            <title>4 to&lt;8 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O4">
            <title>8 to &lt;12 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>8 to&lt;12 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O6">
            <title>8 to&lt;12 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O7">
            <title>12 to &lt;17 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O8">
            <title>12 to&lt;17 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 12 to less than 17 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Effect Concentration Time Curve (AUEC0-1.5) of Baseline-Adjusted Glucose From Time Zero up to 90 Minutes</title>
          <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
          <units>hr*mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.86" spread="26.94"/>
                    <measurement group_id="O2" value="118.82" spread="60.73"/>
                    <measurement group_id="O3" value="142.38" spread="51.98"/>
                    <measurement group_id="O4" value="132.42" spread="22.14"/>
                    <measurement group_id="O5" value="128.82" spread="28.45"/>
                    <measurement group_id="O6" value="138.12" spread="35.24"/>
                    <measurement group_id="O7" value="126.94" spread="30.40"/>
                    <measurement group_id="O8" value="101.46" spread="27.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal and Non-nasal Effects/Symptoms</title>
        <description>Symptoms of runny nose, nasal congestion and/or itching, sneezing, watery and/or itchy eyes, redness of eyes, and itching of ears and/or throat were assessed prior to administering glucagon and at 15, 30, 60 and 90 minutes following administration of glucagon. This was done via the &quot;Nasal Non-nasal Score Questionnaire&quot;. Each of the 9 symptoms is assigned an integer value from 0 to 3; higher values indicate more severe symptoms (a score of 0 indicates no symptoms). The reported results indicate the cohort median out of a possible maximum value of 27 (summing all 9 questions for each participant and reporting the median/IQR across participants).</description>
        <time_frame>Pre-dose;15, 30, 60 and 90 minutes following glucagon administration</time_frame>
        <population>All enrolled participants. One participant in the 8 to &lt;12 group withdrew from the study after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
        <group_list>
          <group group_id="O1">
            <title>4 to&lt;8 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O2">
            <title>4 to&lt;8 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O3">
            <title>4 to&lt;8 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O4">
            <title>8 to &lt;12 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>8 to&lt;12 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O6">
            <title>8 to&lt;12 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O7">
            <title>12 to &lt;17 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O8">
            <title>12 to&lt;17 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 12 to less than 17 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal and Non-nasal Effects/Symptoms</title>
          <description>Symptoms of runny nose, nasal congestion and/or itching, sneezing, watery and/or itchy eyes, redness of eyes, and itching of ears and/or throat were assessed prior to administering glucagon and at 15, 30, 60 and 90 minutes following administration of glucagon. This was done via the &quot;Nasal Non-nasal Score Questionnaire&quot;. Each of the 9 symptoms is assigned an integer value from 0 to 3; higher values indicate more severe symptoms (a score of 0 indicates no symptoms). The reported results indicate the cohort median out of a possible maximum value of 27 (summing all 9 questions for each participant and reporting the median/IQR across participants).</description>
          <population>All enrolled participants. One participant in the 8 to &lt;12 group withdrew from the study after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="2.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O6" value="0.00" lower_limit="0.00" upper_limit="0.50"/>
                    <measurement group_id="O7" value="0.00" lower_limit="0.00" upper_limit="0.50"/>
                    <measurement group_id="O8" value="0.50" lower_limit="0.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post glucagon administration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.00" upper_limit="3.00"/>
                    <measurement group_id="O3" value="0.50" lower_limit="0.00" upper_limit="2.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O5" value="3.00" lower_limit="0.00" upper_limit="4.00"/>
                    <measurement group_id="O6" value="3.00" lower_limit="1.00" upper_limit="4.50"/>
                    <measurement group_id="O7" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post glucagon administration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.00" upper_limit="1.50"/>
                    <measurement group_id="O3" value="0.50" lower_limit="0.00" upper_limit="1.50"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O5" value="2.00" lower_limit="0.00" upper_limit="2.00"/>
                    <measurement group_id="O6" value="2.50" lower_limit="0.50" upper_limit="3.50"/>
                    <measurement group_id="O7" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="1.00" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes post glucagon administration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.00" upper_limit="2.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O6" value="0.50" lower_limit="0.00" upper_limit="1.50"/>
                    <measurement group_id="O7" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="1.00" lower_limit="0.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 minutes post glucagon administration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="1.50"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.50"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O6" value="0.00" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O7" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O8" value="1.00" lower_limit="0.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving at Least a 25 mg/dL Rise in Blood Glucose Above Nadir Level Within 30 Minutes</title>
        <time_frame>Pre-dose; 5, 10, 15, 20, and 30 minutes following glucagon administration</time_frame>
        <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
        <group_list>
          <group group_id="O1">
            <title>4 to&lt;8 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O2">
            <title>4 to&lt;8 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O3">
            <title>4 to&lt;8 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O4">
            <title>8 to &lt;12 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>8 to&lt;12 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O6">
            <title>8 to&lt;12 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O7">
            <title>12 to &lt;17 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O8">
            <title>12 to&lt;17 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 12 to less than 17 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving at Least a 25 mg/dL Rise in Blood Glucose Above Nadir Level Within 30 Minutes</title>
          <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieving â‰¥25 mg/dL Rise in Plasma Glucose Above Nadir Level Within 30 Minutes</title>
        <description>Time (in minutes) when all participants experienced a rise in glucose &gt;=25mg/dL. This is an absolute number and is not a calculated statistic. There is no distribution per cohort.</description>
        <time_frame>Pre-dose; 5, 10, 15, 20, and 30 minutes following glucagon administration</time_frame>
        <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
        <group_list>
          <group group_id="O1">
            <title>4 to&lt;8 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O2">
            <title>4 to&lt;8 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O3">
            <title>4 to&lt;8 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O4">
            <title>8 to &lt;12 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>8 to&lt;12 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O6">
            <title>8 to&lt;12 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O7">
            <title>12 to &lt;17 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O8">
            <title>12 to&lt;17 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 12 to less than 17 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieving â‰¥25 mg/dL Rise in Plasma Glucose Above Nadir Level Within 30 Minutes</title>
          <description>Time (in minutes) when all participants experienced a rise in glucose &gt;=25mg/dL. This is an absolute number and is not a calculated statistic. There is no distribution per cohort.</description>
          <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
          <units>minutes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With &gt;= 25 mg/dL Rise in Plasma Glucose Within 30 Minutes</title>
        <time_frame>Pre-dose; 5, 10,15, 20, and 30 minutes following glucagon administration</time_frame>
        <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
        <group_list>
          <group group_id="O1">
            <title>4 to&lt;8 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O2">
            <title>4 to&lt;8 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O3">
            <title>4 to&lt;8 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 4 to less than 8 years of age.</description>
          </group>
          <group group_id="O4">
            <title>8 to &lt;12 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>8 to&lt;12 Years Old NG Visit 2.0 mg</title>
            <description>NG dose of 2.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O6">
            <title>8 to&lt;12 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 8 to less than 12 years of age.</description>
          </group>
          <group group_id="O7">
            <title>12 to &lt;17 Years Old IM Glucagon Visit</title>
            <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
          </group>
          <group group_id="O8">
            <title>12 to&lt;17 Years Old NG Visit 3.0 mg</title>
            <description>NG dose of 3.0 mg for participants 12 to less than 17 years of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With &gt;= 25 mg/dL Rise in Plasma Glucose Within 30 Minutes</title>
          <population>All enrolled participants that completed the required dosing visit(s). One participant in the 4 to &lt;8 year old 2.0 mg NG group was excluded due to blowing nose after NG administration. One participant in the 8 to &lt;12 group withdrew after completion of the 3.0 mg NG visit and did not complete the 2.0 mg NG visit.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="100"/>
                    <measurement group_id="O7" value="100"/>
                    <measurement group_id="O8" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, up to 69 days</time_frame>
      <desc>Included all participants received at least one dose of glucagon.</desc>
      <group_list>
        <group group_id="E1">
          <title>4 to&lt;8 Years Old IM Glucagon Visit</title>
          <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
        </group>
        <group group_id="E2">
          <title>4 to&lt;8 Years Old NG Visit 2.0 mg</title>
          <description>NG dose of 2.0 mg for participants 4 to less than 8 years of age.</description>
        </group>
        <group group_id="E3">
          <title>4 to&lt;8 Years Old NG Visit 3.0 mg</title>
          <description>NG dose of 3.0 mg for participants 4 to less than 8 years of age.</description>
        </group>
        <group group_id="E4">
          <title>8 to &lt;12 Years Old IM Glucagon Visit</title>
          <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
        </group>
        <group group_id="E5">
          <title>8 to&lt;12 Years Old NG Visit 2.0 mg</title>
          <description>NG of 2.0 mg for participants 8 to less than 12 years of age.</description>
        </group>
        <group group_id="E6">
          <title>8 to&lt;12 Years Old NG Visit 3.0 mg</title>
          <description>NG dose of 3.0 mg for participants 8 to less than 12 years of age.</description>
        </group>
        <group group_id="E7">
          <title>12 to &lt;17 Years Old IM Glucagon Visit</title>
          <description>Participants who weighed at least 25 kg/55 lbs were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 Ibs, IM glucagon dose was 0.5 mg.</description>
        </group>
        <group group_id="E8">
          <title>12 to&lt;17 Years Old NG Visit 3.0 mg</title>
          <description>NG dose of 3.0 mg for participants 12 to less than 17 years of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Experienced a hypoglycemic event after receiving a bolus of insulin with lunch. Received 90 g oral carbohydrates and made a full recovery.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lacrimation increase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

